Page last updated: 2024-11-02

pd 169316 and Injury, Myocardial Reperfusion

pd 169316 has been researched along with Injury, Myocardial Reperfusion in 1 studies

2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole: p38 MAP kinase inhibitor

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Schwertz, H1
Carter, JM1
Abdudureheman, M1
Russ, M1
Buerke, U1
Schlitt, A1
Müller-Werdan, U1
Prondzinsky, R1
Werdan, K1
Buerke, M1

Other Studies

1 other study available for pd 169316 and Injury, Myocardial Reperfusion

ArticleYear
Myocardial ischemia/reperfusion causes VDAC phosphorylation which is reduced by cardioprotection with a p38 MAP kinase inhibitor.
    Proteomics, 2007, Volume: 7, Issue:24

    Topics: Animals; Antibodies, Phospho-Specific; Cardiotonic Agents; Electrophoresis, Gel, Two-Dimensional; He

2007